Growth hormone and IGF-1: the longevity trade-off behind an anti-ageing pitch

The relationship between growth hormone, its downstream messenger IGF-1, and lifespan is a trade-off rather than a fountain of youth: the same signalling that builds muscle and bone in youth appears to accelerate ageing, and people born with lifelong growth-hormone deficiency are strikingly protected from cancer and diabetes [s1]. Given as an anti-ageing therapy to healthy older adults, growth hormone shifts body composition modestly but raises the rate of adverse events and has never been shown to extend life — which is why its distribution as an anti-ageing agent is illegal in the United States [s3].

The clue from a rare mutation

The sharpest evidence for the trade-off comes from a community in Ecuador whose members carry mutations in the growth-hormone receptor gene, causing severe GH and IGF-1 deficiency — a condition known as Laron syndrome. Researchers monitored these individuals for 22 years and compared them with unaffected relatives [s1]. Among those with the deficiency there was only one non-lethal malignancy and no cases of diabetes, against a prevalence of 17% for cancer and 5% for diabetes in the control group [s1]. They also had markedly lower insulin concentrations (1.4 versus 4.4 µU/ml) and a much lower insulin-resistance index (HOMA-IR 0.34 versus 0.96), indicating high insulin sensitivity [s1].

This mirrors animal genetics, where mutations that dampen GH/IGF-1 signalling extend lifespan across species [s1]. Less growth signalling, in this reading, means less of the pro-ageing, pro-cancer stimulus — a benefit that runs in exactly the opposite direction from the anti-ageing marketing of growth hormone.

Where the anti-ageing pitch came from

The commercial case rests largely on a single small study from 1990. Twelve men aged 61 to 81 received human growth hormone at roughly 0.03 mg per kilogram three times a week for six months, which raised their IGF-1 into the range typical of young adults [s2]. Their lean body mass rose 8.8%, adipose-tissue mass fell 14.4%, and lumbar spine bone density rose 1.6% [s2]. Those numbers, from 12 men over six months, became the foundation of a decades-long industry — even though the study measured body composition, not health, ageing or survival, and its own later commentary in the journal cautioned against exactly that extrapolation [s2].

What the pooled evidence shows

When the trials are gathered, the body-composition effect is real and small and the safety picture is not reassuring. A 2007 systematic review pooled 18 study populations totalling 220 people who received GH [s3]. Compared with controls, fat mass fell by 2.1 kg (95% CI, −2.8 to −1.35) and lean body mass rose by 2.1 kg (1.3 to 2.9), while total body weight did not change significantly [s3]. But those treated with GH were significantly more likely to develop soft-tissue swelling, joint pain, carpal tunnel syndrome and gynecomastia, and somewhat more likely to develop diabetes or impaired fasting glucose [s3]. The authors concluded that GH cannot be recommended as an anti-ageing therapy, and noted that its distribution for that purpose is illegal in the United States [s3].

A separate 26-week randomised trial in healthy adults aged 65 to 88 found the same shape: growth hormone increased lean body mass — in women, by 1.0 kg versus 0.4 kg on placebo (P = .001) — but the trial was designed around adverse effects precisely because they were expected [s4]. The muscle you can measure comes bundled with the harms you can measure.

The honest summary

Growth hormone reliably nudges body composition — more lean mass, less fat — and just as reliably raises the rate of oedema, joint pain, carpal tunnel syndrome and glucose problems, with no evidence of longer or healthier life [s3][s4]. Meanwhile the human "experiment" that points toward longevity is the opposite intervention: less GH/IGF-1 signalling, not more [s1]. That is the core contradiction anyone selling GH for ageing has to talk around.

It also explains why lowering IGF-1 keeps recurring as a desirable signal elsewhere in ageing research — it is one of the changes seen with calorie restriction and sits inside the insulin/IGF-1 axis mapped among the hallmarks of ageing. The clinical reality of too much GH is visible from the other end in acromegaly, the disease of growth-hormone excess — not a state anyone should induce in the name of staying young.

This article describes research findings and is not medical advice.